Related Experiment Video
Updated: Aug 13, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Disease-modifying drugs for progressive rheumatoid arthritis
For rheumatoid arthritis patients unresponsive to basic treatments, stronger drugs like hydroxychloroquine, gold, and azathioprine are considered. This review details their pharmacology, clinical studies, and toxicity profiles.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) often requires advanced therapies when initial treatments fail.
- Salicylates and nonsteroidal anti-inflammatory agents (NSAIDs) are common first-line RA treatments.
Purpose of the Study:
- To review alternative drug options for RA patients refractory to standard therapies.
- To provide an overview of the pharmacology, clinical efficacy, and toxicity of second-line RA medications.
Main Methods:
- Literature review of pharmacological data.
- Analysis of pertinent clinical studies.
- Evaluation of toxicity profiles for specific RA drugs.
Main Results:
- Hydroxychloroquine, gold compounds, penicillamine, azathioprine, and cyclophosphamide are discussed.
- Each agent's pharmacology, mechanism of action, and clinical trial outcomes are presented.
- Key toxicities associated with these stronger RA medications are highlighted.
Conclusions:
- These advanced RA therapies offer alternatives for non-responders.
- Careful consideration of pharmacology and toxicity is crucial for patient management.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
